ICAD icad Inc.

iCAD to Participate at the Piper Healthcare Conference

iCAD to Participate at the Piper Healthcare Conference

NASHUA, N.H., Nov. 26, 2019 (GLOBE NEWSWIRE) -- (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael Klein, Chairman and Chief Executive Officer, will present a corporate overview at the Piper Healthcare Conference, taking place December 3-5, 2019 in New York City.

  
Presentation Details:
Date: December 5, 2019
Time: 9:50am Eastern Time
Webcast: 
  

About iCAD, Inc.

Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit .

Contact:

Media Inquiries:

Jessica Burns, iCAD 



Investor Relations:

Jeremy Feffer, LifeSci Advisors

8

EN
26/11/2019

Underlying

ICADicad Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on icad Inc.

 PRESS RELEASE
Free
ICAD ICAD INC.

iCAD Announces Proxy Advisory Firms ISS and Glass Lewis Recommend Stoc...

iCAD Announces Proxy Advisory Firms ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Acquisition by RadNet, Inc. NASHUA, N.H., July 08, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”), a global leader in clinically proven AI-powered cancer detection solutions, today announced that leading independent proxy advisory firms Institutional Shareholder Services Inc. (“ISS”) and Glass, Lewis & Co. (“Glass Lewis”) have each recommended that stockholders vote “FOR” the previously announced acquisition of the Company by RadNet, Inc. (“RadNet”) at the Compa...

July 8, 2025 1 EN
 PRESS RELEASE
Free
ICAD ICAD INC.

iCAD Reports Financial Results for First Quarter Ended March 31, 2025

iCAD Reports Financial Results for First Quarter Ended March 31, 2025 NASHUA, N.H., May 13, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three months ended March 31, 2025.  First Quarter 2025 Highlights (Year over Year Performance): Total ARR (Annual Recurring Revenue) was $10.7 million, up 18% year over yearQ1 total revenues of $4.9 millionGross Profit Margin o...

May 13, 2025 1 EN
 PRESS RELEASE
Free
ICAD ICAD INC.

iCAD Collaborates with Microsoft to provide access to its Mammography ...

iCAD Collaborates with Microsoft to provide access to its Mammography Solutions in Microsoft’s Precision Imaging Network (PIN) iCAD collaborates with Microsoft to offer radiology providers the option for automated patient reporting on mammography results through PowerScribe integration NASHUA, N.H., April 29, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: ICAD) (“iCAD” or the “Company”), a global leader in clinically proven AI-powered cancer detection solutions, announced today a collaboration with Microsoft, to include a set of AI-powered mammography solutions in iCAD’s ProFound Breast Health Sui...

April 29, 2025 1 EN
 PRESS RELEASE
Free
ICAD ICAD INC.

iCAD Expands Executive Leadership with Appointment of Mark Koeniguer a...

iCAD Expands Executive Leadership with Appointment of Mark Koeniguer as Chief Commercial Officer NASHUA, N.H., April 08, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today announced the appointment of Mark Koeniguer as Chief Commercial Officer (CCO), to lead the next phase of global growth for iCAD. As CCO at iCAD, Koeniguer will assume responsibilities for revenue growth across North America and around the globe, bringi...

April 8, 2025 1 EN
 PRESS RELEASE
Free
ICAD ICAD INC.

iCAD Reports Financial Results for Fourth Quarter and Fiscal Year Ende...

iCAD Reports Financial Results for Fourth Quarter and Fiscal Year Ended December 31, 2024 NASHUA, N.H., March 19, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the fourth quarter and full year ended December 31, 2024.  Fourth Quarter 2024 Highlights (Year-over-Year Performance): Total ARR (Annual Recurring Revenue) was $9.8 million, up 11% year over yearTotal revenue...

March 19, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch